Wedbush assumed coverage on shares of Aktis Oncology (NASDAQ:AKTS – Free Report) in a research note published on Wednesday morning, Marketbeat Ratings reports. The firm issued an outperform rating and a $35.00 price objective on the technology company’s stock.
A number of other brokerages also recently commented on AKTS. Weiss Ratings raised Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. HC Wainwright upped their price objective on Aktis Oncology from $33.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, June 2nd. William Blair began coverage on Aktis Oncology in a research report on Wednesday, April 29th. They set an “outperform” rating for the company. Raymond James Financial started coverage on shares of Aktis Oncology in a report on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target on the stock. Finally, Wall Street Zen lowered shares of Aktis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, July 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $35.00.
View Our Latest Stock Analysis on AKTS
Aktis Oncology Price Performance
Aktis Oncology (NASDAQ:AKTS – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The technology company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The company had revenue of $3.38 million for the quarter, compared to analyst estimates of $2.70 million. As a group, research analysts expect that Aktis Oncology will post -1.8 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, Director Ken Herrmann sold 4,856 shares of the company’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the transaction, the director owned 3,506 shares in the company, valued at approximately $86,107.36. This represents a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 3.30% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the company. State of Wyoming bought a new position in shares of Aktis Oncology during the 2nd quarter worth $32,000. AXQ Capital LP bought a new stake in Aktis Oncology in the 2nd quarter valued at about $226,000. Susquehanna International Group LLP purchased a new stake in Aktis Oncology during the second quarter valued at about $278,000. Deutsche Bank AG lifted its holdings in Aktis Oncology by 49.3% during the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after purchasing an additional 6,942 shares during the last quarter. Finally, Great Lakes Advisors LLC bought a new position in Aktis Oncology during the second quarter worth about $1,406,000. Hedge funds and other institutional investors own 28.84% of the company’s stock.
Aktis Oncology Company Profile
Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.
The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.
Featured Articles
- Five stocks we like better than Aktis Oncology
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
